Krystal Biotech KRYS
NASDAQ KRYS
$311.39 -8.74 (-2.73%)
As of: Oct 23, 2026 · 3:59 PM EDT

Krystal Biotech (KRYS) Amortization of Deferred Charges (2019 - 2020)

Updated

Analysis

Krystal Biotech (KRYS) Amortization of Deferred Charges (2019 - 2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Krystal Biotech 9.22 Bn 5.99 Bn 112.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 26,000.00
Dec 31, 2019 26,000.00
Sep 30, 2019 68,000.00
Jun 30, 2019 65,000.00
Mar 31, 2019 67,000.00
API Access

Krystal Biotech Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=KRYS&period=max&api_key=YOUR_API_KEY